LEO Pharma Open Innovation

FAQs

This list contains the answers to questions we often get asked.

Q1 - How is LEO Pharma Open Innovation different from other forms of collaboration? LEO Pharma Open Innovation openly discloses the science we offer and some of our corporate interests. We also provide open and free access to some of our specialised research capabilities, without asking for any commitments from you, the partner.

Q2 - What is LEO Pharma Open Innovation? Traditionally there has been a barrier between pharmaceutical companies’ research and that of outside researchers. LEO Pharma Open Innovation is a collaborative space created to explore partnerships and the latest research using disease-relevant in vitro assays as an initial stepping stone towards finding the next generation of treatments for skin disease together. The open innovation platform allows insight and access to some of LEO Pharma's unique research tools in order to test external molecules for disease-relevant effects, but without the obligation to disclose confidential information (such as the structure of your molecule) or to relinquish intellectual property. By openly disclosing the assays we offer and some of our corporate interests, we hope that someone out there will have a resource, piece of information or an idea that we didn’t know about before, to provide a solution for people with skin diseases.

Q3 - Does 'open' mean that everything will be revealed to everyone? No, it does not. 'Open' in this context refers to the open disclosure and availability of our disease-relevant assays. Participation in LEO Pharma Open Innovation is an agreement between LEO Pharma and you, the partner. Your decision, compounds, results and conclusion will not be kept confidential by us, and not communicated to anyone outside of LEO Pharma, unless specifically agreed.

Q4 - What is the Agreement or MTA? The document which you can download here is an agreement between LEO Pharma and you (the partner) which specifies the details, including securing confidentiality and what we do in the collaboration. It covers what sometimes is referred to as a Material Transfer Agreement (MTA). It also states that LEO Pharma will not use the compounds in any other way than agreed upon and that you consider some points when agreeing to nominate compounds for testing in the LEO Pharma Open Innovation platform. One of the main points of the contract is to ensure that the your assets (molecules) are safe and protected.

Q5 - Can anyone participate in LEO Pharma Open Innovation? As long as you are a recognised company or institution and provide the necessary registration information– yes! However, LEO Pharma can choose not to allow access if the registration criteria are not met, or if there is a potential issues with LEO Pharma code of conduct or business otherwise.

Q6 - Will you test absolutely anything? LEO Pharma Open Innovation invites you to test compounds you believe will have an effect in the disclosed in vitro assays, and to explore science with the intention of further collaboration. We will not filter or select what we test, but by giving you the details of the assays we hope that you can make a sensible judgement on whether your molecule has the potential to produce an interesting result. However, if we for any reason suspect. a hazard issue we will of course not test or handle such a molecule.

Q7 - Can you test an antibody we've developed? Currently our assays are designed to test compounds dissolved in DMSO, not water, so we cannot test compounds that are not stable in DMSO. However, we're working on optimising some changes to the protocols which will allow us to test water-based compounds in the near future.